Halozyme Therapeutics (HALO) Competitors $58.56 +1.02 (+1.77%) Closing price 04:00 PM EasternExtended Trading$58.58 +0.02 (+0.03%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HALO vs. BIIB, INCY, UTHR, NBIX, EXEL, BMRN, EXAS, MDGL, RGEN, and IONSShould you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Madrigal Pharmaceuticals (MDGL), Repligen (RGEN), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. Halozyme Therapeutics vs. Its Competitors Biogen Incyte United Therapeutics Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Exact Sciences Madrigal Pharmaceuticals Repligen Ionis Pharmaceuticals Biogen (NASDAQ:BIIB) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends. Which has more volatility & risk, BIIB or HALO? Biogen has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Do insiders & institutionals believe in BIIB or HALO? 87.9% of Biogen shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 0.2% of Biogen shares are owned by insiders. Comparatively, 2.4% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable earnings and valuation, BIIB or HALO? Biogen has higher revenue and earnings than Halozyme Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B1.98$1.63B$10.1312.93Halozyme Therapeutics$1.02B7.11$444.09M$3.7615.57 Is BIIB or HALO more profitable? Halozyme Therapeutics has a net margin of 44.76% compared to Biogen's net margin of 15.07%. Halozyme Therapeutics' return on equity of 136.91% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.07% 14.03% 8.32% Halozyme Therapeutics 44.76%136.91%26.05% Do analysts recommend BIIB or HALO? Biogen presently has a consensus target price of $186.37, indicating a potential upside of 42.29%. Halozyme Therapeutics has a consensus target price of $62.70, indicating a potential upside of 7.07%. Given Biogen's stronger consensus rating and higher possible upside, equities analysts clearly believe Biogen is more favorable than Halozyme Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 21 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.34Halozyme Therapeutics 2 Sell rating(s) 6 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.17 Does the media favor BIIB or HALO? In the previous week, Biogen had 38 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 50 mentions for Biogen and 12 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.18 beat Biogen's score of 0.72 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 23 Very Positive mention(s) 4 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryHalozyme Therapeutics beats Biogen on 9 of the 16 factors compared between the two stocks. Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HALO vs. The Competition Export to ExcelMetricHalozyme TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.09B$2.99B$5.57B$9.43BDividend YieldN/A2.44%4.05%3.99%P/E Ratio15.5721.1128.0520.07Price / Sales7.11329.78451.48104.76Price / Cash12.3741.9636.1958.45Price / Book20.488.198.605.83Net Income$444.09M-$55.10M$3.24B$258.27M7 Day Performance0.95%7.71%4.63%3.98%1 Month Performance10.91%21.81%12.93%14.89%1 Year Performance5.70%6.57%35.40%19.29% Halozyme Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HALOHalozyme Therapeutics4.8177 of 5 stars$58.56+1.8%$62.70+7.1%+5.9%$7.09B$1.02B15.57390News CoveragePositive NewsBIIBBiogen4.9315 of 5 stars$133.11-0.8%$188.48+41.6%-43.6%$19.50B$9.68B13.147,605Analyst UpgradeINCYIncyte4.5937 of 5 stars$69.98+2.0%$74.47+6.4%+5.7%$13.55B$4.24B218.692,617Upcoming EarningsInsider TradeUTHRUnited Therapeutics4.9831 of 5 stars$297.68+0.7%$383.08+28.7%-10.4%$13.43B$2.88B11.881,305Positive NewsUpcoming EarningsNBIXNeurocrine Biosciences4.4834 of 5 stars$135.13+1.3%$163.91+21.3%-8.6%$13.37B$2.41B45.811,800Upcoming EarningsAnalyst ForecastEXELExelixis4.8352 of 5 stars$45.58+1.6%$45.22-0.8%+96.8%$12.43B$2.17B20.721,147Positive NewsUpcoming EarningsAnalyst ForecastBMRNBioMarin Pharmaceutical4.9861 of 5 stars$58.23+0.2%$93.78+61.1%-30.6%$11.17B$2.85B21.653,040Analyst ForecastAnalyst RevisionEXASExact Sciences4.7667 of 5 stars$54.30+4.6%$70.50+29.8%+3.5%$10.24B$2.76B-9.857,000Upcoming EarningsMDGLMadrigal Pharmaceuticals4.2834 of 5 stars$319.87+1.4%$420.63+31.5%+9.2%$7.10B$180.13M-17.7290News CoverageInsider TradeRGENRepligen4.624 of 5 stars$121.33-6.8%$170.75+40.7%-11.9%$6.82B$650.43M-269.621,778Upcoming EarningsAnalyst UpgradeAnalyst RevisionIONSIonis Pharmaceuticals4.5788 of 5 stars$42.55+2.0%$58.25+36.9%-17.1%$6.77B$717.25M-14.231,069News CoveragePositive NewsUpcoming EarningsAnalyst Revision Related Companies and Tools Related Companies BIIB Competitors INCY Competitors UTHR Competitors NBIX Competitors EXEL Competitors BMRN Competitors EXAS Competitors MDGL Competitors RGEN Competitors IONS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HALO) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HALO Stock Alerts